MARKET

IMRX

IMRX

Immuneering Corp
NASDAQ
1.260
-0.020
-1.56%
After Hours: 1.290 +0.03 +2.38% 19:06 05/14 EDT
OPEN
1.260
PREV CLOSE
1.280
HIGH
1.305
LOW
1.220
VOLUME
149.13K
TURNOVER
--
52 WEEK HIGH
3.830
52 WEEK LOW
1.000
MARKET CAP
45.34M
P/E (TTM)
-0.6400
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMRX last week (0505-0509)?
Weekly Report · 2d ago
Immuneering Price Target Cut to $21.00/Share From $25.00 by Oppenheimer
Dow Jones · 05/07 14:07
Immuneering Is Maintained at Outperform by Oppenheimer
Dow Jones · 05/07 14:07
Oppenheimer Maintains Outperform on Immuneering, Lowers Price Target to $21
Benzinga · 05/07 13:58
IMMUNEERING CORPORATION <IMRX.O>: OPPENHEIMER CUTS TARGET PRICE TO $21 FROM $25
Reuters · 05/07 12:08
Immuneering price target lowered to $21 from $25 at Oppenheimer
TipRanks · 05/07 12:03
Positive Outlook for Immuneering: Buy Rating Backed by Strategic Developments and Promising Clinical Data
TipRanks · 05/07 08:15
Immuneering Corp. Reports Promising Q1 2025 Results
TipRanks · 05/07 04:40
More
About IMRX
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Webull offers Immuneering Corp stock information, including NASDAQ: IMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMRX stock methods without spending real money on the virtual paper trading platform.